BB BIOTECH AG · ISIN: CH0038389992 · EQS - Company News

Substantial pipeline progress at several portfolio companies offsets rate-related market volatility

Media release as at July 26, 2024 Portfolio of BB Biotech AG as at June 30, 2024 Substantial pipeline progress at several portfolio companies offsets rate-related market volatility Global equity indices climbed to new record highs during the second quarter, driven by just a few mega tech stocks, but investors continued to shun the healthcare sector. BB Biotech’s shares closed the period 12.0% lower in CHF and 11.3% lower in EUR. A net loss of CHF 87 mn was incurred in the second quarter compa...

SIX:BION Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News BB BIOTECH AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (6)
Short Selling (DE) (1)
Short Selling (UK) (0)
26 July 2024 07:00AM
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
CH0038389992
Media release as at July 26, 2024 Portfolio of BB Biotech AG as at June 30, 2024 Substantial pipeline progress at several portfolio companies offsets rate-related market volatility Global equity indices climbed to new record highs during the second quarter, driven by just a few mega tech stocks, but investors continued to shun the healthcare sec...
BB BIOTECH AG
About the publication
20 May 2024 12:53PM
A recovering sector with a healthy prognosis
CH0038389992
  London, UK, 20 May 2024   Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial...
Edison Investment Research Limited
About the publication
21 March 2024 06:00PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
CH0038389992
Media release of March 21, 2024 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
About the publication
16 February 2024 07:00AM
BB Biotech AG publishes its 2023 annual report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR February 16, 2024 Annual report of BB Biotech AG as at December 31, 2023  BB Biotech AG publishes its 2023 annual report BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
About the publication
14 February 2024 07:00AM
Investor interest returns – dividend yield remains high for 2024
CH0038389992
Release as at February 14, 2024Investor interest returns – dividend yield remains high for 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of inves...
BB BIOTECH AG
About the publication
19 January 2024 07:00AM
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR January 19, 2024 BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Results for the financial year 2023 Based on its preliminary unaudited ...
BB BIOTECH AG
About the publication
19 January 2024 07:00AM
End of year biotech equity market rally – M&A and end of rate hike cycle
CH0038389992
Media release as at January 19, 2024 Portfolio of BB Biotech AG as at December 31, 2023 End of year biotech equity market rally – M&A and end of rate hike cycle In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond ma...
BB BIOTECH AG
About the publication
20 October 2023 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR October 20, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2023, which covers the results of its business activities for the first nine months of 2023. Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
About the publication
20 October 2023 07:00AM
the impact of rising bond yields and shifting healthcare policies
CH0038389992
Media release as at October 20, 2023 Interim report of BB Biotech AG as at September 30, 2023 Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies Expectations that the US central bank would soon reverse its monetary policy stance proved to be premature. The rise in bond yields weighed heavily on biot...
BB BIOTECH AG
About the publication
21 July 2023 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR July 21, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023. Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
About the publication
21 July 2023 07:00AM
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
CH0038389992
Media release as at July 21, 2023 Interim report of BB Biotech AG as at June 30, 2023 Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry The first half of 2023 has been disappointing for biotech investors. A massive rotation has put biotech stocks under pressure. Whereas...
BB BIOTECH AG
About the publication
21 July 2023 07:00AM
BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
CH0038389992
Media release as at July 21, 2023 Interim report of BB Biotech AG as at June 30, 2023 Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry The first half of 2023 has been disappointing for biotech investors. A massive rotation has put biotech stocks under pressure. Whereas...
BB BIOTECH AG
About the publication
21 July 2023 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR July 21, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023. Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
About the publication
03 May 2023 07:00AM
Creating blockbuster drugs using algorithms
CH0038389992
Expert commentary Creating blockbuster drugs using algorithms Artificial intelligence is becoming an increasingly important tool in the drug discovery and development process. Biotech investors benefit from this technology too. Dr. Samuel Croset, Data Scientist BB Biotech at Bellevue Asset Management Artificial intelligence and machine-learning...
BB BIOTECH AG
About the publication
03 May 2023 07:00AM
BB BIOTECH AG: Creating blockbuster drugs using algorithms
CH0038389992
Expert commentary Creating blockbuster drugs using algorithms Artificial intelligence is becoming an increasingly important tool in the drug discovery and development process. Biotech investors benefit from this technology too. Dr. Samuel Croset, Data Scientist BB Biotech at Bellevue Asset Management Artificial intelligence and machine-learning...
BB BIOTECH AG
About the publication
21 April 2023 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR April 21, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023. Based on the consolidated accounts of BB Biotech AG, net loss for ...
BB BIOTECH AG
About the publication
21 April 2023 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR April 21, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023. Based on the consolidated accounts of BB Biotech AG, net loss for ...
BB BIOTECH AG
About the publication
21 April 2023 07:00AM
Lackluster first quarter for biotech stocks
CH0038389992
Media release as at April 21, 2023 Interim report of BB Biotech AG as at March 31, 2023 Lackluster first quarter for biotech stocks Concerns about capital market resilience clearly had an impact on investor preferences during the first quarter. After a strong start to the year, market sentiment switched to risk-off and this triggered heavy sellin...
BB BIOTECH AG
About the publication
21 April 2023 07:00AM
BB BIOTECH AG: Lackluster first quarter for biotech stocks
CH0038389992
Media release as at April 21, 2023 Interim report of BB Biotech AG as at March 31, 2023 Lackluster first quarter for biotech stocks Concerns about capital market resilience clearly had an impact on investor preferences during the first quarter. After a strong start to the year, market sentiment switched to risk-off and this triggered heavy sellin...
BB BIOTECH AG
About the publication
23 March 2023 05:45PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
CH0038389992
Media release of March 23, 2023 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
About the publication
23 March 2023 05:45PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
CH0038389992
Media release of March 23, 2023 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
About the publication
17 February 2023 07:00AM
BB Biotech AG publishes its 2022 annual report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR February 17, 2023 Annual report of BB Biotech AG as at December 31, 2022  BB Biotech AG publishes its 2022 annual report BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
About the publication
17 February 2023 07:00AM
BB Biotech AG publishes its 2022 annual report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR February 17, 2023 Annual report of BB Biotech AG as at December 31, 2022  BB Biotech AG publishes its 2022 annual report BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
About the publication
20 January 2023 07:00AM
BB Biotech AG closes the 2022 fiscal year with a loss
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR January 20, 2023 BB Biotech AG closes the 2022 fiscal year with a loss In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022. Based on its preliminary unaudited consolidated figures, BB ...
BB BIOTECH AG
About the publication
20 January 2023 07:00AM
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
CH0038389992
Media release as at January 20, 2023 Portfolio of BB Biotech AG as at December 31, 2022 Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85  The year 2022 saw volatile market conditions for global equity and bond markets, with substantial stepwise increases in central bank rates, led by the US ...
BB BIOTECH AG
About the publication
08 December 2022 05:00PM
BB BIOTECH AG: Molecular strike force for the immune system
CH0038389992
Market commentary, December 8, 2022 Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management Molecular strike force for the immune system The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities. Autoim...
BB BIOTECH AG
About the publication
08 December 2022 05:00PM
Molecular strike force for the immune system
CH0038389992
Market commentary, December 8, 2022 Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management Molecular strike force for the immune system The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities. Autoim...
BB BIOTECH AG
About the publication
21 October 2022 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR October 21, 2022 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022. Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
About the publication
21 October 2022 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR October 21, 2022 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022. Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
About the publication
21 October 2022 07:00AM
US drug pricing legislation drives biotech business to adapt for further innovation
CH0038389992
Media release as at October 21, 2022 Interim report of BB Biotech AG as at September 30, 2022 US drug pricing legislation drives biotech business to adapt for further innovation Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid...
BB BIOTECH AG
About the publication
21 October 2022 07:00AM
BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
CH0038389992
Media release as at October 21, 2022 Interim report of BB Biotech AG as at September 30, 2022 US drug pricing legislation drives biotech business to adapt for further innovation Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid...
BB BIOTECH AG
About the publication
30 August 2022 11:00AM
Moderna was just the beginning
CH0038389992
Market commentary, August 30, 2022 Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management Moderna was just the beginning RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years. Alnylam, a stock in BB Biotech's portfolio, ...
BB BIOTECH AG
About the publication
30 August 2022 11:00AM
BB BIOTECH AG: Moderna was just the beginning
CH0038389992
Market commentary, August 30, 2022 Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management Moderna was just the beginning RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years. Alnylam, a stock in BB Biotech's portfolio, ...
BB BIOTECH AG
About the publication
22 July 2022 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR July 22, 2022 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022. Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
About the publication
22 July 2022 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 LR July 22, 2022 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022. Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
About the publication
22 July 2022 07:00AM
BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
CH0038389992
Media release as at July 22, 2022 Interim report of BB Biotech AG as at June 30, 2022 First signs of increased M&A activity due to attractive valuations The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year con...
BB BIOTECH AG
About the publication
22 July 2022 07:00AM
First signs of increased M&A activity due to attractive valuations
CH0038389992
Media release as at July 22, 2022 Interim report of BB Biotech AG as at June 30, 2022 First signs of increased M&A activity due to attractive valuations The second quarter was distinguished by a difficult macroeconomic environment and, particularly, by stubbornly high inflation. The broad market corrections that began earlier in the year con...
BB BIOTECH AG
About the publication
24 May 2022 07:30AM
BB BIOTECH AG: Disruptive technologies are changing an entire industry
CH0038389992
Market commentary, 24 May 2022 Dr. Daniel Koller, Head Investment Team BB Biotech at Bellevue Asset Management Disruptive technologies are changing an entire industry The biotech industry is increasingly applying next-generation therapeutic approaches to develop drugs for diseases and conditions with larger populations of patients. The sales pot...
BB BIOTECH AG
About the publication
22 April 2022 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules April 22, 2022 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022. Based on the consolidated accounts of BB Biot...
BB BIOTECH AG
About the publication
22 April 2022 07:00AM
BB BIOTECH AG: Increased investment level balanced by established core holdings
CH0038389992
Media release as at April 22, 2022 Interim report of BB Biotech AG as at March 31, 2022 Increased investment level balanced by established core holdings Markets were subject to large swings in valuation during the first quarter of 2022. A broad sell-off during the first two months was followed by a strong rebound in March. The biotechnology sect...
BB BIOTECH AG
About the publication
12 April 2022 07:00AM
BB Biotech AG concludes its share buyback program and launches a new buyback program
CH0038389992
Media Release of April 12, 2022 BB Biotech AG concludes its share buyback program and launches a new buyback program Yesterday, April 11, 2022, BB Biotech AG concluded the share buyback program it had initiated on April 12, 2019. During this period no registered shares were repurchased via a second trading line. The Board of Directors passed a m...
BB BIOTECH AG
About the publication
17 March 2022 06:00PM
Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
CH0038389992
Media release of March 17, 2022 Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of t...
BB BIOTECH AG
About the publication
18 February 2022 08:05AM
BB Biotech AG publishes its 2021 annual report
CH0038389992
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules February 18, 2022 Annual report of BB Biotech AG as at December 31, 2021 BB Biotech AG publishes its 2021 annual report BB Biotech AG published its annual report for fiscal year 2021 today. Besides the audited consolidated financial statements, the annual report contains detailed i...
BB BIOTECH AG
About the publication
18 February 2022 07:00AM
BB Biotech AG publishes its 2021 annual report
CH0038389992
Media release as at February 18, 2022 Annual report of BB Biotech AG as at December 31, 2021 BB Biotech AG publishes its 2021 annual report BB Biotech AG published its annual report for fiscal year 2021 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Bi...
BB BIOTECH AG
About the publication
21 January 2022 07:00AM
BB Biotech AG closes the 2021 fiscal year with a loss
CH0038389992
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules January 21, 2022 BB Biotech AG closes the 2021 fiscal year with a loss In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2021. Based on its preliminary unaudited cons...
BB BIOTECH AG
About the publication
21 January 2022 07:00AM
BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
CH0038389992
Media release as at January 21, 2022 Portfolio of BB Biotech AG as at December 31, 2021 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed The year 2021 was a volatile market environment for all involved in biotechnology investing, including BB Biotech. The biotech and pharmaceutical sector adapted to ...
BB BIOTECH AG
About the publication
22 October 2021 07:00AM
BB Biotech AG publishes its interim report
CH0038389992
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules October 22, 2021 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2021, which covers the results of its business activities for the first nine months of 2021. Based on the consolidated accounts of B...
BB BIOTECH AG
About the publication
22 October 2021 07:00AM
BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS
CH0038389992
Media release of October 22, 2021 Interim report of BB Biotech AG as at September 30, 2021 BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS Healthcare markets traded higher in July and August but lost ground in September and ended the third quarter in line with the broader market. BB Biote...
BB BIOTECH AG
About the publication
More BB BIOTECH AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 6 19th September 2024 von Planta, Dr. Thomas DD
Short Seller (DE) 1 15th December 2016 Elliott Capital Advisors, L.P. SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN